Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (stock code: 2268.HK) [1][3] Core Insights - WuXi AppTec reported a revenue of 5.944 billion RMB for 2025, representing a year-on-year growth of 46.7%. The adjusted net profit reached 1.559 billion RMB, up 69.9% year-on-year, with a gross profit of 2.139 billion RMB, reflecting a 72.5% increase. The adjusted EBITDA was 1.962 billion RMB, marking a 66.7% growth [3][4] - The company's operational efficiency is improving, with a significant expansion in project pipelines and orders on hand. The gross margin increased to 36.0%, and the adjusted profit margin reached 26.2%, both hitting historical highs. The total amount of uncompleted orders is 1.5 billion USD, a 50.3% increase year-on-year, with a market share exceeding 24% [3][4] - The company signed 70 new iCMC projects in 2025, with 252 ongoing iCMC projects and 18 PPQ projects. WuXi AppTec has empowered clients to submit 38 IND applications, collaborating with 643 global clients and submitting over 120 INDs. Notably, 14 of the top 20 global pharmaceutical companies are now partners, contributing approximately 32% of revenue [3][4] - The company's technological platforms, including WuXiDARx™, X-LinC, and WuXi Tecan-1&Tecan-2, continue to lead the industry, accelerating the development of new conjugated drugs. In 2025, over 5,600 ADC/XDC molecules were researched, covering various advanced molecular types [3][4] - WuXi AppTec's production capacity and layout are undergoing comprehensive upgrades, with the Wuxi base achieving integrated production of antibody intermediates, conjugated solutions, and formulations. The DP3 production line received GMP approval in July 2025, and additional DP capacity is expected to double by 2029 [3][4] Financial Projections - The projected total revenue for 2026 is 8.55 billion RMB, with a growth rate of 43.83%. The net profit attributable to the parent company is expected to be 2.111 billion RMB, reflecting a growth rate of 42.59% [4][5] - By 2028, the total revenue is projected to reach 15.338 billion RMB, with a net profit of 3.83 billion RMB, indicating a growth rate of 31.22% [4][5] - The current price-to-earnings (P/E) ratio is 33 for 2026, decreasing to 18 by 2028, indicating a favorable valuation trend [4][5]

Core Viewpoint - The report highlights that WuXi AppTec (药明合联) is positioned as a leading player in the global ADC CXO industry, expected to solidify its market leadership due to its advanced technology and product delivery quality amidst rapid industry expansion [1][2]. Financial Performance - In the first half of 2025, the company achieved revenue of 2.7 billion yuan, a year-on-year increase of 62.2%, with a gross profit of 980 million yuan, up 82.2% year-on-year [2]. - Adjusted net profit (excluding interest and expenses) reached 730 million yuan, reflecting a 69.6% year-on-year growth, while the net profit was 750 million yuan, a 52.7% increase [2]. - The company’s revenue projections for 2025-2027 are 5.99 billion, 8.24 billion, and 10.51 billion yuan, with year-on-year growth rates of 47.7%, 37.7%, and 27.5% respectively [1]. Order Backlog and Market Position - As of the first half of 2025, the company’s unfulfilled order total reached 1.33 billion USD, a 57.9% increase year-on-year, with new contract amounts growing by 48.4% [2]. - The global ADC market is projected to reach 13.2 billion USD in 2024, with a compound annual growth rate (CAGR) of 34.0% from 2020 to 2024, and expected to grow to 66.2 billion USD by 2030 [2]. Strategic Expansion and Capital Expenditure - The company signed 37 new iCMC projects in the first half of 2025, maintaining a robust expansion of its project funnel model [3]. - For 2025, the company plans capital expenditures of 1.56 billion yuan, with significant investments in its Singapore and Wuxi bases, and total capital expenditures expected to exceed 7 billion yuan by 2029 [3].

Core Viewpoint - 中邮证券 initiates coverage on WuXi AppTec with a "Buy" rating, highlighting strong growth in revenue and net profit for the first half of 2025 [1] Financial Performance - Company reported revenue of 2.7 billion yuan for the first half of 2025, representing a year-on-year growth of 62.2% [1] - Net profit reached 750 million yuan, showing a year-on-year increase of 52.7% [1] Project and Order Growth - Total number of iCMC projects reached 225, with 37 new iCMC projects signed in the first half of the year, marking a historical high [1] - The company has an unfulfilled order total of 1.33 billion USD, reflecting a year-on-year growth of 57.9% [1] - New contract amount increased by 48.4% year-on-year, with North America showing the highest growth rate compared to other regions [1] Market Position and Future Projections - Company is recognized as a leading global ADC CXO enterprise, with a comprehensive R&D technology platform [1] - Revenue projections for 2025 to 2027 are 5.75 billion, 7.83 billion, and 10.17 billion yuan, with year-on-year growth rates of 42%, 36%, and 30% respectively [1] - Net profit projections for the same period are 1.6 billion, 2.26 billion, and 3.02 billion yuan, with year-on-year growth rates of 50%, 41%, and 34% respectively [1]

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant revenue and profit growth, indicating robust operational momentum and effective market strategies [1][2]. Financial Performance - In 25H1, the company achieved revenue of 2.7 billion yuan, representing a year-on-year increase of 62.2% - Net profit reached 750 million yuan, up 52.7% year-on-year - Adjusted net profit, excluding interest income, was 730 million yuan, reflecting a 69.6% increase [1]. Revenue Breakdown - The revenue from IND before and after was 41% and 59% respectively, consistent with the structure from 24H1, although the IND after revenue share slightly decreased compared to 24H1 - North America remained the largest region, contributing 52% to total revenue in 25H1, an increase of 2 percentage points from 24 - Europe accounted for 22% of revenue, surpassing China's 18%, driven by strong performance in overseas licensing, NewCo models, and M&A activities [1][2]. Profitability Metrics - The company's gross margin improved by 4.0 percentage points year-on-year to 36.1% in 25H1, compared to 30.6% in 24 - The increase in gross margin was attributed to higher capacity utilization in production lines, particularly in the DS/DP segments, and the rapid ramp-up of the new BCM2 L2 production line initiated in November 24 - The adjusted net profit margin (excluding interest income) rose by 1.2 percentage points year-on-year to 27.1% [1]. Project and Capacity Expansion - As of 25H1, the company had a total of 225 iCMC projects, with 37 new projects signed in the first half, marking a historical high - The company also signed 3 new PPQ projects, totaling 11 projects - The total uncompleted order amount reached 1.33 billion USD, up 57.9%, with new contract amounts increasing by 48.4%, particularly in North America [2]. Production Capacity - All production lines, including BCM1, BCM2 L1, BCM2 L2, DP1, and DP2, are operating at high capacity - The third conjugate agent production workshop, DP3, successfully completed GMP release by the end of July 25 - The new Singapore base achieved mechanical completion in June 25 and is entering the equipment and facility debugging phase, with GMP release expected in 26H1 [2]. Capital Expenditure - The company anticipates capital expenditures of 1.56 billion yuan for 25, with approximately 900 million yuan allocated to the Singapore base and about 450 million yuan to the Wuxi base - By 29, total capital expenditures are expected to exceed 7 billion yuan, supporting rapid growth through domestic and international capacity expansion [2]. Investment Outlook - The company is positioned as a leading global ADC CXO enterprise with a comprehensive R&D platform and a growing customer base and project count - Revenue projections for 25, 26, and 27 are 5.75 billion, 7.83 billion, and 10.17 billion yuan, respectively, with year-on-year growth rates of 42%, 36%, and 30% - Expected net profits for the same years are 1.6 billion, 2.26 billion, and 3.02 billion yuan, with growth rates of 50%, 41%, and 34% respectively, leading to a PE ratio of 53, 37, and 28 times [3].